Get started
Author

Erica N Boswell

Breast cancer and sexual function.
2015 · Erica N Boswell, Don S Dizon · PubMed · 90
Drug-Related Pneumonitis During Mammalian Target of Rapamycin Inhibitor Therapy: Radiographic Pattern-Based Approach in Waldenström Macroglobulinemia as a Paradigm
2015 · Mizuki Nishino, Erica N. Boswell, et al. · The Oncologist · 52
PDF
Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia
2013 · Irene M. Ghobrial, Federico Campigotto, et al. · Blood · 47
Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia
2015 · I M Ghobrial, R Redd, et al. · Leukemia · 32
Phase I/II Trial Of Everolimus, Bortezomib and Rituximab In Relapsed Or Relapsed/Refractory Waldenstrom's Macroglobulinemia
2013 · Irene M. Ghobrial, Erica N Boswell, et al. · Blood · 5
Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy In Relapsed Or Relapsed/Refractory Multiple Myeloma
2013 · Irene M. Ghobrial, Kenneth Shain, et al. · Blood · 5
Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenstrom Macroglobulinemia
2014 · Irene M. Ghobrial, Robert Allyn Redd, et al. · Blood · 4
Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma
2014 · Irene M. Ghobrial, Jacob P. Laubach, et al. · Blood · 4
A Phase 1/2 Trial of TH-302 and Dexamethasone without or with Bortezomib (TBorD) in Patients with Relapsed/Refractory Multiple Myeloma
2014 · Jacob P. Laubach, Noopur S. Raje, et al. · Blood · 3
Phase I study of TH-302, an investigational hypoxia-targeted drug, and dexamethasone in patients with relapsed/refractory multiple myeloma.
2013 · Irene M. Ghobrial, Jacob Laubach, et al. · Journal of Clinical Oncology · 3
Comparative miRNA Expression Profiling of Circulating Exosomes From MGUS and Smoldering Multiple Myeloma Patients
2012 · Salomon Manier, Erica N Boswell, et al. · Blood · 3
Preliminary safety and efficacy of evofosfamide (TH-302), an investigational hypoxia-activated prodrug, combined with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma (RR MM).
2015 · Jacob Laubach, Noopur S. Raje, et al. · Journal of Clinical Oncology · 2
Final Results of the Phase II Trial of Single Agent Panobinostat (LBH589) in Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia
2011 · Irene M. Ghobrial, Ranjit Banwait, et al. · Blood · 2
Phase I Trial of Everolimus and Rituximab or Everolimus, Bortezomib and Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia
2011 · Irene M. Ghobrial, Erica N Boswell, et al. · Blood · 2
Prognostic Value of Circulating Exosomal microRNAs in 112 Patients with Multiple Myeloma
2014 · Salomon Manier, Herve Avet-Loiseau, et al. · Blood · 1
Preliminary safety and efficacy of TH-302, an investigational hypoxia-targeted drug, and dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RR MM).
2014 · Jacob Laubach, Noopur S. Raje, et al. · Journal of Clinical Oncology · 1
Phase 1 Study Of TH-302, An Investigational Hypoxia-Targeted Drug, and Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma
2013 · Irene M. Ghobrial, Jacob P. Laubach, et al. · Blood · 1
Mirna Expression Profiling and Proteomic Analysis Of Circulating Exosomes From Multiple Myeloma Patients
2013 · Salomon Manier, Erica N Boswell, et al. · Blood · 1
Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom macroglobulinemia.
2012 · Irene M. Ghobrial, Morie A. Gertz, et al. · Journal of Clinical Oncology · 1
CLINICAL TRIALS AND OBSERVATIONS Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia
2017 · Irene M. Ghobrial, Federico Campigotto, et al.
LNA Anti-MicroRNA-155: A Novel Therapeutic Strategy in Waldenstrom Macroglobulinemia and Chronic Lymphocytic Leukemia
2011 · Yong Zhang, Christopher P. Rombaoa, et al. · Blood
Works count: 21
Citation count: 259
H-index: 5
I10-index: 4
Year
Topic
Type